PATH

PATH'S GLOBAL HEALTH PROGRAMS DIVISION WORKS IN PARTNERSHIP WITH GOVERNMENTS AND COMMUNITIES TO TURN PROVEN HEALTH INNOVATIONS INTO REAL-WORLD SOLUTIONS THAT REACH THE PEOPLE WHO NEED THEM MOST. WE STRENGTHEN PRIMARY HEALTH CARE SYSTEMS BY EXPANDING ACCESS TO LIFESAVING TOOLS LIKE MALARIA PREVENTIVES AND HIV SERVICES. WE FOCUS ON BUILDING EVIDENCE, IMPROVING EFFICIENCY, AND SUPPORTING LOCAL HEALTH WORKERS - OFTEN USING DIGITAL TOOLS AND DATA TO GUIDE SMARTER DECISIONS. RATHER THAN DELIVERING CARE DIRECTLY, WE EQUIP HEALTH SYSTEMS TO DO IT BETTER, FASTER, AND MORE EQUITABLY. OUR GOAL IS INTEGRATED, PERSON-CENTERED CARE THAT SPANS DISEASES AND GEOGRAPHIES, MAKING CARE MORE ACCESSIBLE, EFFECTIVE, AND ALIGNED WITH THE NEEDS OF THE PEOPLE IT SERVES. (CONTINUED ON SCHEDULE O)IN 2024, PATH'S GLOBAL HEALTH PROGRAMS DIVISION:- REACHED 9.1 MILLION PEOPLE WITH QUALITY HEALTH CARE. - STRENGTHENED 93 LOCAL PARTNERS.KEY ACHIEVEMENTS INCLUDE, BUT ARE NOT LIMITED TO:- MALARIA PREVENTION AND SURVEILLANCEPATH'S MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) LAUNCHED THE FOUR-YEAR MACEPA V GRANT, EXPANDING ITS TECHNICAL SUPPORT ACROSS SEVEN COUNTRIES. THE TEAM SUPPORTED NATIONAL MALARIA PROGRAMS IN THE CENTRAL AFRICAN REPUBLIC, THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC), ETHIOPIA, THE GAMBIA, NIGERIA, SENEGAL, AND ZAMBIA, ADVANCING PRIORITIES IN SURVEILLANCE, COMMUNITY CASE MANAGEMENT, DATA USE, AND STRATEGIC PLANNING. ACTIVITIES INCLUDED TAILORED OPERATIONAL PLANNING, ANALYTIC AND MODELING SUPPORT, SURVEILLANCE SYSTEM ASSESSMENTS, AND CAPACITY STRENGTHENING FOR NATIONAL MALARIA PROGRAMS.THROUGH THE REACH GLOBAL MALARIA PROJECT, PATH SUPPORTED SEASONAL PREVENTION CAMPAIGNS THAT REACHED OVER 2 MILLION CHILDREN ACROSS MALI AND TOGO WITH LIFESAVING MEDICINE. THE PROJECT ALSO PARTNERED WITH NATIONAL PROGRAMS IN SEVEN COUNTRIES TO IMPROVE SERVICE DELIVERY AND QUALITY OF CARE.- OXYGEN THERAPY AND EQUIPMENT ACCESSTO ENSURE MEDICAL OXYGEN REACHES PATIENTS WHO NEED IT, PATH LAUNCHED A CENTRALIZED PROCUREMENT PILOT ACROSS 14 COUNTRIES. THE NEW MODEL CUT TRANSACTION COSTS BY 26% AND REDUCED LEAD TIMES BY UP TO SIX MONTHS, HELPING HOSPITALS KEEP ESSENTIAL SYSTEMS RUNNING IN COUNTRIES ACROSS LATIN AMERICA, THE MIDDLE EAST, AND SUB-SAHARAN AFRICA.IN THE DRC, WE ALSO HELPED MEDICAL SCHOOLS INTEGRATE OXYGEN THERAPY INTO THEIR CORE CURRICULUM AND LAUNCHED A NEW HANDS-ON TRAINING CENTER AT THE UNIVERSITY OF KINSHASA, EQUIPPING HUNDREDS OF FUTURE DOCTORS WITH LIFESAVING RESPIRATORY CARE SKILLS.- STRENGTHENING PRIMARY HEALTH CAREIN UKRAINE, PATH EXPANDED HEPATITIS C SERVICES THROUGH THE UNITAID-FUNDED HEPC3P PROJECT, SUPPORTING COMMUNITY-LED APPROACHES AT OPIOID TREATMENT CENTERS. THIS INCLUDED NEW SELF-TESTING TOOLS, PEER-LED RESEARCH, AND INCREASED ACCESS TO HARM REDUCTION SERVICES.IN INDONESIA, WITH SUPPORT FROM THE GATES FOUNDATION, WE HELPED LOCAL HEALTH OFFICIALS IMPROVE HOW PEOPLE EXPERIENCE PRIMARY CARE BY CONNECTING SERVICES AROUND INDIVIDUALS RATHER THAN DISEASES.

PATH'S PRODUCT DEVELOPMENT DIVISION MAKES SURE THE RIGHT HEALTH PRODUCTS REACH THE PEOPLE WHO NEED THEM - AFFORDABLY, EFFECTIVELY, AND EQUITABLY. WE DEVELOP VACCINES, DIAGNOSTICS, MEDICAL DEVICES, AND DRUG FORMULATIONS FOR LOW-RESOURCE SETTINGS - FROM EARLY-STAGE RESEARCH THROUGH LICENSURE, QUALITY TESTING, AND INTRODUCTION. AS A PRODUCT DEVELOPMENT PARTNERSHIP, WE ACT AS THE GLUE - CONNECTING PRIVATE-SECTOR MANUFACTURERS, NATIONAL HEALTH PROGRAMS, AND COMMUNITIES. WE MAKE SURE LIFESAVING HEALTH PRODUCTS ARE DESIGNED FOR REAL-WORLD CONDITIONS, NOT JUST HIGH-INCOME MARKETS - BECAUSE HEALTH EQUITY BEGINS WITH ACCESS.(CONTINUED ON SCHEDULE O)IN 2024, PATH'S PRODUCT DEVELOPMENT DIVISION:- REACHED 9.4 MILLION PEOPLE WITH QUALITY HEALTH CARE. - STRENGTHENED 153 LOCAL PARTNERS. KEY ACHIEVEMENTS INCLUDE, BUT ARE NOT LIMITED TO:- POLIO ERADICATIONPATH LED THE GLOBAL DEVELOPMENT AND DELIVERY OF NOVEL ORAL POLIO VACCINE TYPE 2, A SAFER, MORE GENETICALLY STABLE VACCINE DESIGNED TO STOP OUTBREAKS CAUSED BY VACCINE-DERIVED STRAINS. MORE THAN 1 BILLION DOSES HAVE NOW BEEN ADMINISTERED WORLDWIDE. PATH RECEIVED THE INNOVATING FOR IMPACT AWARD FROM THE GLOBAL HEALTH TECHNOLOGIES COALITION FOR ITS LEADERSHIP OF THIS EFFORT. IN THE DRC, PATH HELPED LAUNCH THE CONGO RIVER STRATEGY, REACHING REMOTE COMMUNITIES BY CANOE TO VACCINATE CHILDREN LIVING ALONG THE RIVERBANKS.- SAFER MALARIA TREATMENT WITH G6PD TESTINGPATH HELPED CO-DEVELOP THE FIRST POINT-OF-CARE TEST FOR G6PD DEFICIENCY TO RECEIVE WORLD HEALTH ORGANIZATION (WHO) PREQUALIFICATION. THE STANDARD G6PD TEST USES A SIMPLE FINGER PRICK AND DELIVERS RESULTS IN UNDER TWO MINUTES, PROVIDING SAFER TREATMENT OF P. VIVAX MALARIA AND REDUCING RISK OF DANGEROUS DRUG REACTIONS, ESPECIALLY FOR WOMEN WITH INTERMEDIATE DEFICIENCY LEVELS.- IMPROVING DIAGNOSIS AND CARE FOR SICK CHILDRENTHROUGH THE TOOLS FOR INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS PROJECT, PATH INTRODUCED PULSE OXIMETERS AND DIGITAL DECISION-SUPPORT TOOLS TO CLINICS IN TANZANIA, KENYA, SENEGAL, AND INDIA. THE TOOLS IMPROVED CARE FOR OVER 200,000 CHILDREN AND SUPPORTED TRAINING FOR MORE THAN 1,400 HEALTH WORKERS.- VACCINE INNOVATION THROUGH MICROARRAY PATCHES (MAPS)PATH SUPPORTED HUMAN FACTORS EVALUATIONS OF TWO MAP CANDIDATES FOR MEASLES-RUBELLA VACCINATION IN KENYA, NEPAL, AND THE DRC. THESE NEEDLE-FREE, HEAT-STABLE PATCHES WERE WIDELY ACCEPTED BY PROVIDERS AND CAREGIVERS. IF SCALED, THEY COULD HELP REACH 80 MILLION ADDITIONAL CHILDREN AND PREVENT 35% MORE MEASLES CASES BETWEEN 2030 AND 2040.- PROGRESS IN CERVICAL CANCER PREVENTIONPATH GENERATED CRITICAL EVIDENCE FOR A SINGLE-DOSE HPV VACCINE SCHEDULE USING CECOLIN, A LOW-COST, WHO-PREQUALIFIED VACCINE. GHANA APPROVED CECOLIN IN 2024 AND IS NOW WORKING TOWARD LOCAL PRODUCTION, THEREBY ADVANCING THE AFRICAN UNION'S GOAL TO PRODUCE 60% OF ITS VACCINES ON THE CONTINENT BY 2040.